Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$27.04
▲ $0.09 (+0.3%)
Market data updated: 09/30 07:44 PM
Fundamentals updated: 09/30/2026
News analyzed: 09/30/2026
Market Cap
$23.73B
Day Range
$26.85 - $27.23
52-Week Range
$26.40 - $37.51
Beta
—
Next Earnings
04.11.2026
Support
$26.40
Resistance
$32.92
SNN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-25.5% (1Y)
Strengths: 9/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 52.3%
Growth
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.13 (3y annualized return 4.0% / max drawdown 31.1%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
50
Momentum
30
Risk
56
Sentiment
92
Fundamental
68
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Smith & Nephew (SNN) has focused on its financial valuation and analyst sentiment, with multiple firms initiating coverage or rating the company as neutral. Analysts highlight its undervalued status, citing strong profitability and moderate growth, while a recent partnership with Imperial College for surgical robotics was noted. Additionally, there was a brief mention of the company’s role in industry shifts, such as a CFO hire at Baxter. No major operational or earnings updates were prominently featured.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Smith & Nephew SNATS, Inc.. News trend score: 92. Reason: 9 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
40
Psychology
55
Fundamentals
68
Technical
30
Valuation
50
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-11%
Market Narrative
55
Fundamental Reality
40
Narrative Gap
+15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a dominant herding dynamic, where traders align with peers (-3.6% move) rather than fundamentals or technical extremes. Elevated volume (1.49x) and positive sentiment (92/100) coexist with negative momentum (-4.1%), indicating a cautious but synchronized reaction. Anchoring (81) may reinforce near-term support fixation, while FOMO and panic signals are muted by technical weakness. The key question: *Will traders break from the herd if price tests support, or will anchoring sustain the group’s collective stance?*
Updated: 09/08/2026, 04:37 PM
What could change this?
👥 What the crowd believes
"BTIG Initiates Smith & Nephew at Neutral"
"weak orthopedics, a guidance cut, and exec turnover"
"SMITH & NEPHEW (SNN) passes Decent Value screen with strong valuation, profitability, and moderate growth. Forward P/E 10.85, dividend 2.95%"
"SNN Advances Surgical Robotics Through Imperial College Partnership"
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 87/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 31/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with the highest scores coming from technical and growth-oriented investors like Samuel Armstrong Nelson (91), who sees it as oversold and cyclically favorable, and Peter Lynch (76), who views it as a growth stock undervalued relative to its potential. Meanwhile, behavioral and value-focused thinkers like Charles Mackay (76) and Thorstein Veblen (72) agree it lacks crowd-driven hype or speculative excess, while disciplined traders like Jack Schwager (69) and long-term hold advocates like Edgar Lawrence Smith (67) see it as a structured, high-conviction opportunity. However, the split becomes stark when contrasting these bullish perspectives with the more cautious or skeptical verdicts: Howard Marks (54) flags potential overvaluation, while the efficient-market camp (Malkiel/Bogle, 50) dismisses it as unexceptional compared to broader indices. Benjamin Graham’s methods (31–33) outright reject it for lacking defensive value, and Jesse Livermore’s (23) strict trend-following rule sees it as a red flag. The debate thus hinges on whether the stock’s cyclical or growth tailwinds justify its risk—or if it’s already priced for those assumptions.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 87
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 77
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 72
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 67
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 67
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 65
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 64
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 63
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 61
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 59
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 53
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 45
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 33
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 31
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 290 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
68.3%
Operating Margin
12.9%
Net Margin
10.1%
EBITDA Margin
—
ROE
11.8%
ROA
6.0%
ROIC
—
EPS
$0.72
Cash
$557.00M
Total Debt
—
Current Ratio
2.57
Debt/Equity
0.63
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 27.3.2026 | $0.482 |
| 26.3.2026 | $0.482 |
| 3.10.2025 | $0.300 |
| 2.10.2025 | $0.300 |
| 28.3.2025 | $0.462 |
| 27.3.2025 | $0.462 |
| 4.10.2024 | $0.288 |
| 3.10.2024 | $0.288 |
| 1.4.2024 | $0.462 |
| 31.3.2024 | $0.462 |
| 5.10.2023 | $0.288 |
| 4.10.2023 | $0.288 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$6.22
Tangible Book Value per Share (Tangible NAV)
$5.19
Sentiment based on basic keywords (not AI) — 9 positive, 9 neutral, 2 negative out of the last 20 articles.
Yahoo · 28.9.2026
Yahoo · 23.9.2026
Yahoo · 23.9.2026
Yahoo · 22.9.2026
Benzinga · 22.9.2026
Yahoo · 21.9.2026
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
MT Newswires · 8.9.2026
Yahoo · 8.9.2026
ACCESS Newswire · 8.9.2026
Benzinga · 8.9.2026
Benzinga · 8.9.2026
MT Newswires · 4.9.2026
Yahoo · 4.9.2026
MT Newswires · 31.8.2026
Benzinga · 31.8.2026
Benzinga · 31.8.2026
Smith & Nephew SNATS, Inc. (SNN) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SNN currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
SNN's technical score is 30/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 52.3%; Net income growth: 51.7%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Calmar: 0.13 (3y annualized return 4.0% / max drawdown 31.1%); Price is below the 50-day average; Price is below the 200-day average.
Yes — SNN has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,832,632 shares short as of 2026-09-15 · vs. 6,240,013 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.2% of trading volume this week was short selling, vs. 55.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology